Testing intermittent ibrutinib for advanced chronic lymphocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and able to read, understand, and sign consent.
- You have CLL/SLL that needs treatment after chemo failed, or you have a high-risk genetic change (17p and/or TP53) even if treatment history differs.
- You have already taken ibrutinib for at least 6 months and your disease improved to at least a “partial response” clinically.
- Your overall health is good enough for study visits (ECOG 0 to 2).
- Blood and organ tests must meet minimum levels (white blood cells, platelets, kidney function, and liver enzymes within allowed ranges).
- You must not be pregnant or breastfeeding, and you must use reliable contraception if you can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
This trial studies an approach for people with newly diagnosed CLL/SLL (chronic lymphocytic leukemia or related disease) who need treatment. It tests whether alternating two types of chemotherapy with ibrutinib (a targeted pill) can control the disease better and safely.
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
This study looks at how safe and effective ibrutinib is over the long term, either alone or together with nivolumab. You may join if you are already in an earlier ibrutinib study and your care team feels staying on ibrutinib is worth the risk.
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.